Le Lézard
Classified in: Health
Subjects: PDT, TRI, FDA

FDA approves first-in-human trial for neural-enabled prosthetic hand system developed at FIU


MIAMI, March 28, 2017 /PRNewswire-USNewswire/ -- Upper extremity amputees are one step closer to successfully picking up a cookie and an egg, thanks to a new advanced prosthetic system that is designed to restore sensation.

The U.S. Food and Drug Administration (FDA) has granted an investigational device exemption for the first-in-human trial with this technology. The system was developed at Florida International University by Ranu Jung and her Adaptive Neural Systems Laboratory team.

"The system is intended to restore the sense of touch, and hand opening which would allow users to precisely differentiate the size and fragility of various objects," said Ranu Jung, interim dean of the College of Engineering and Computing and a Wallace H. Coulter Eminent Scholars Chair in biomedical engineering. "The prostheses that exist today make it difficult for amputees to manipulate delicate and small objects because they can't feel them."

Jung's technology, a neural-enabled prosthetic hand system (NEPH), stimulates nerves in the arm to provide sensation as the person is using the prosthetic hand. The prosthetic system has the first fully implantable, wirelessly controlled Class-III device with electrodes that can be surgically implanted within the nerves of the residual arm.

"The system reflects an almost decade-long collaborative team effort. For the first time, amputees will be able to use a fully implantable, sensory enabled prosthetic hand system at home for daily activities and researchers will be able to assess the long term clinical impact of its use in real-world environments," said Jung.

Similar to a pacemaker, the system works by delivering small electrical pulses to specific nerves in the arm. Wires as thin as a hair strand are placed within nerve bundles in the arm and connected to an electrical stimulator. Sensors embedded in the prosthetic hand send signals wirelessly to the implanted stimulator, which then elicits sensation by delivering weak electrical pulses via the implanted electrodes. As a result, the person should be able to sense their hand opening position and grip items when the prosthetic hand encounters an object.

Participants in the trial will be able to use the system outside of the laboratory on a daily basis. At this time, the NEPH system is not approved by the FDA for U.S. commercial distribution, but if this first-in-human trial is successful, Jung and her team plan to continue testing through larger clinical trials and eventually seek such approval.

The system can potentially be interfaced with several different advanced prosthetic hands that are currently being developed commercially or under government support. Jung has spent the last decade developing the prosthetic hand system with the assistance of a Bioengineering Research Partnership grant from the National Institutes of Health (NIH), specifically its National Institute of Biomedical Imaging and Bioengineering (NIBIB) and Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD).

"This research journey started from foundational neuroscience and engineering principles to incorporating with painstaking accuracy the validation needed to make this system ready for clinical studies and this first-in-human trial. This unique system, integrating the long-term efforts of academia and industry, is an example of the bioengineering partnerships we promote," said Grace Peng, Ph.D., Program Director at NIBIB.

The HAPTIX program of the Defense Advanced Research Projects Agency (DARPA), which is an agency of the Department of Defense, is now supporting the first-in-human trial of the system. Florida International University, with Jung as principal investigator, will receive up to $2.2 million in support of this first-in-human trial.

The system and studies have been developed in collaboration with James Abbas, a professor at the School of Biological and Health Systems Engineering at Arizona State University. Industry partners include Cochlear Ltd (Australia), Motion Control, div. of Fillauer Companies, Inc. (Utah), Nikao Inc. (Florida) and clinical teams from the Miami Hand & Upper Extremity Institute (Florida) and Ortho Pro (Florida).

Click here for a video about the neural-enabled prosthetic hand system.

Click here for a GIF of the neural-enabled prosthetic hand system in action.

NOTE: Currently, the Neural Enabled Prosthetic Hand System (ANS-NEPH) is limited by federal (or United States) law to investigational use. The research is sponsored by the Defense Advanced Research Projects Agency's (DARPA) Hand Proprioception and Touch Interfaces (HAPTIX) program and the Army Research Office (ARO) under Grant Number W911NF-17-1-0022."

Media Contact:
Millie Acebal
305-348-7762
[email protected]

Jessica Drouet
305-348-6944
[email protected]
news.fiu.edu 
@FIUNews

 

SOURCE Florida International University


These press releases may also interest you

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:16
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...

at 16:15
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...



News published on and distributed by: